Get the Stockscreener App
18.14
9.25%
-1.85
After Hours:
18.05
-0.09
-0.50%
Dianthus Therapeutics Inc stock is traded at $18.14, with a volume of 332.71K.
It is down -9.25% in the last 24 hours and down -16.02% over the past month.
See More
Previous Close:
$19.99
Open:
$19.22
24h Volume:
332.71K
Relative Volume:
1.21
Market Cap:
$638.33M
Revenue:
$4.12M
Net Income/Loss:
$-56.68M
P/E Ratio:
-3.2727
EPS:
-5.5429
Net Cash Flow:
$-51.44M
1W Performance:
-6.54%
1M Performance:
-16.02%
6M Performance:
-33.75%
1Y Performance:
-39.53%
1-Day Range:
$18.00
$19.57
1-Week Range:
$17.50
$20.45
52-Week Range:
$17.50
$32.27
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
18.14 | 638.33M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Swiss National Bank Sells 2,900 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Trading 6.5% HigherHere's Why - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week LowWhat's Next? - MarketBeat
Charles Schwab Investment Management Inc. Acquires 1,092 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Deep Track Capital, LP Acquires Significant Stake in Dianthus Th - GuruFocus
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.8%Here's What Happened - MarketBeat
Avidity Partners Management LP Increases Stake in Dianthus Thera - GuruFocus
Cantor Fitzgerald Issues Positive Estimate for DNTH Earnings - MarketBeat
HC Wainwright Brokers Raise Earnings Estimates for DNTH - MarketBeat
FY2025 Earnings Forecast for DNTH Issued By Lifesci Capital - MarketBeat
Wedbush Equities Analysts Reduce Earnings Estimates for DNTH - MarketBeat
FY2025 EPS Estimates for DNTH Raised by Cantor Fitzgerald - Defense World
HC Wainwright Reaffirms "Buy" Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
HC Wainwright Issues Optimistic Outlook for DNTH Earnings - Defense World
Dianthus Therapeutics' (DNTH) Outperform Rating Reiterated at Wedbush - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap DownWhat's Next? - MarketBeat
Dianthus Therapeutics (DNTH) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 5.5%Here's Why - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Issues Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Research Analysts Set Expectations for DNTH Q1 Earnings - Defense World
HC Wainwright Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Guggenheim Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Wedbush Reaffirms “Outperform” Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates - MSN
Dianthus Therapeutics' (DNTH) "Buy" Rating Reaffirmed at Guggenheim - MarketBeat
We're Not Very Worried About Dianthus Therapeutics' (NASDAQ:DNTH) Cash Burn Rate - Yahoo Finance
Dianthus Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Dianthus Therapeutics (DNTH) to Release Quarterly Earnings on Thursday - Defense World
Dianthus Therapeutics Reports 2024 Financial Results and Clinical Progress - TipRanks
Stifel maintains Buy rating on Dianthus Therapeutics stock By Investing.com - Investing.com Canada
Dianthus Therapeutics shares fall as Q4 results miss expectations By Investing.com - Investing.com South Africa
Dianthus Therapeutics shares fall as Q4 results miss expectations - Investing.com India
Optimistic Buy Rating for Dianthus Therapeutics Driven by Promising DNTH103 Data and Pipeline Progress - TipRanks
Dianthus Therapeutics: Strong Financials and Promising Clinical Trials Justify Buy Rating - TipRanks
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of “Buy” by Brokerages - Defense World
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results - The Manila Times
Dianthus Therapeutics, Inc. /DE/ SEC 10-K Report - TradingView
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 - Bluefield Daily Telegraph
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):